Navigation Links
HIV positive and HIV negative patients have similar survival rates following liver transplant
Date:4/24/2009

Copenhagen, Denmark, Friday 24 April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.

The study results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5% and 74% versus 87.1% and 78%, p=0.843), suggesting a good prognosis for HIV positive patients following liver transplant. However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53% in HIV positive patients with hepatitis C versus 87% and 69% (p=0.047) in HIV negative patients with hepatitis C.

Doctor Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London, who led the study said: "Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment. However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease. In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."

The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in HIV patients undergoing liver transplant in the UK. They examined 6,315 adult patients (>18 years) undergoing their first liver transplant between March 1994 and April 2008. The patient groups compared in this analysis included:

  1. HIV positive patients who tested negative for both hepatitis C and hepatitis B
  2. HIV negative patients with hepatitis C
  3. HIV positive patients with hepatitis C

The three patient groups were comparable according to the Model End Stage Liver Disease (MELD) scores, which is a numerical scale to score disease severity and improve organ allocation in transplantation. HIV positive patients were younger compared to HIV negative patients (mean 42.2 years versus 51.2, p=0.001) and HIV positive patients co-infected with hepatitis C were younger (mean 39.9 years versus 51.8; p=0.0001) than HIV negative patients with hepatitis C.


'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-078-761-90439
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
2. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. Economy Got You Down? Use The Principles Of Positive Psychology
5. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
6. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
7. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
8. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
9. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
10. Positive behavior support training curriculum
11. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... LaserShip, a ... water to the Food Bank of Eastern Michigan last Friday in order to aid ... footprint into the Midwest to include a facility located in Clio, only 15 miles ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on ... Medicine , an emergency medicine professional association, to support the organization's newly established ... American Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians to ...
(Date:2/10/2016)... ... , ... Emergency rooms provide emergency care to stabilize critical health issues, but ... dental emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron Family ... new dental patients and families in the North Metro Denver area. The new dental ... to cosmetic dentistry, and all in the most relaxing environment. , While some dental ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial ... --> --> Financial ... $9.45 billion, up 28% on a constant currency basis ... billion. Excluding the impact of the acquisition of Abbott ... (the "EPD Business"), full year adjusted total revenues increased ...
(Date:2/10/2016)... February 10, 2016 A new report from business intelligence ... states that the Alzheimer,s disease market will more than double from just under ... Compound Annual Growth Rate (CAGR) of 11%. Canada , ... , Spain , the UK, and Japan ... forecast period. --> Canada , France ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
Breaking Medicine Technology: